Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling

Overview of attention for article published in Breast Cancer Research, April 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (54th percentile)
Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 9 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 7,731 followers.

RT @cancerscnews: Researchers at Capital Medical University explored the impacts of DCLK1 on tumor cells as well as their immune microenvir…

23 Apr 2023

Reply Repost Favourite

Researchers at Capital Medical University explored the impacts of DCLK1 on tumor cells as well as their immune microenvironment in #TNBC and potential therapeutic strategies for TNBC patients with high DCLK1 expression. 🔖 https://t.co/SKxqDLHIoQ https://t

23 Apr 2023

Reply Repost Favourite

RT @Dr_Ivanoncologo: The IL-6/STAT3 pathway activated by DCLK1 could improve the efficacy of chemotherapy by activating antitumor immunity,…

23 Apr 2023

Reply Repost Favourite

The IL-6/STAT3 pathway activated by DCLK1 could improve the efficacy of chemotherapy by activating antitumor immunity, resulting in a promising treatment in #TNBC. https://t.co/aMGb6HaDfZ https://t.co/0MqIilfaxt

21 Apr 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.